Repligen
RGEN
#2580
Rank
$6.99 B
Marketcap
$123.95
Share price
0.99%
Change (1 day)
4.54%
Change (1 year)
Categories

P/E ratio for Repligen (RGEN)

P/E ratio as of June 2026 (TTM): 135

According to Repligen 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 134.728. At the end of 2025 the company had a P/E ratio of 188.

P/E ratio history for Repligen from 2001 to 2026

PE ratio at the end of each year

Year P/E ratio Change
2025188-166.73%
2024-282-217.73%
2023240375.76%
202250.4-55.48%
2021113-32.67%
2020168-18.22%
201920648.11%
2018139179.26%
201749.7-43.56%
201688.1-9.73%
201597.623.17%
201479.2184.52%
201327.8103.9%
201213.7

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Pfizer
PFE
20.0-85.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
27.0-79.94%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
39.5-70.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
16.1-88.08%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
-0.4998-100.37%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
4.00-97.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
23.6-82.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
72.8-45.97%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
40.9-69.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
-61.3-145.47%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.